We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Nanion’s SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp (APC) Users

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Nanion’s SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp (APC) Users"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The SyncroPatch 96 is Nanion’s high throughput screening platform, capable of generating 9000 data points per day. Since the launch earlier this year, the SyncroPatch 96 platform has been validated with a wide variety of ion channels and cell types, including challenging ligand gated channels such as α7 nicotinic acetylcholine receptors.

Dr. Adam Hendricson, Lead Evaluation, Bristol-Myers Squibb, CT, USA, says:
“The flexibility of the SyncroPatch 96 to run ligand-gated assays without sacrificing throughput or fidelity relative to voltage-gated channels really sets it apart in the gigaseal auto-EP space. When considering different platforms, the SyncroPatch was the only system that met all our critical criteria: >50% giga-seal across multiple cell lines, minimal chip priming and cell-handling, rapid solution exchange for fast agonists, internal solution exchange, ability to multiplex cells in a run, compatibility with external robotic automation, and a highly competitive cost per data point. We run the SyncroPatch on a daily basis and are very happy with its performance and efficiency, and with the excellent, highly responsive applications support offered by Nanion.”

Dr. Henning Draheim, Boehringer-Ingelheim, Germany, continues:
“We carefully researched the market before looking closer at selected APC platforms that may match our internal criteria. We were very impressed by the SyncroPatch 96 system’s flexibility and data quality when testing it on-site, finding that it really performs “as advertised” and definitely fits our needs. In addition, Nanion performed a blind study on the SyncroPatch, testing 22 of our compounds, using a protocol addressing the block of sodium channels in their inactivated state. The obtained compound pharmacology was compared to our manual patch clamp data and the match was fantastic! For me, it was then a straightforward decision for the SyncroPatch 96 and of course it is great when the data speaks for itself when one needs to convince the upper management to purchase state-of-art equipment.”